Q-omics provides the consensus-scored RPS15AP17 profile across patient tissues and cancer cell-line models. RPS15AP17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RPS15AP17 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, RPS15AP17 RNA expression shows 12,583 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, COAD, and THYM as cancer lineages where RPS15AP17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15AP17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15AP17 survival associations across molecular data types. RPS15AP17 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15AP17 RNA expression–survival associations across cancer types. High RPS15AP17 expression shows unfavorable associations in LIHC, ACC, BRCA and DLBC, but favorable associations in THCA and BLCA. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify THCA as the clearest survival context for RPS15AP17 RNA expression.
This table summarizes RPS15AP17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS15AP17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15AP17 shows higher tumor expression in COAD, KIRP, KIRC, CHOL, LIHC and LUAD. The COAD box plot shows higher RPS15AP17 RNA expression in tumor versus normal tissue (log2 FC = +0.932, t-test p < 0.001).
This table shows molecular features associated with RPS15AP17 in patient tissues and cancer cell lines. In patient samples, RPS15AP17 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
